John Carroll, M.D., professor of medicine at the University of Colorado School of Medicine, and director of interventional cardiology at the University of Colorado Hospital, explains his late-breaker presentation data at ACC.16. He researched outcomes and procedural volume based on the transcatheter aortic valve replacement (TAVR) STS/ACC TVT Registry.
VIDEO: Teleflex Talks Complex Interventions at TCT 2018
In 2009, the GuideLiner Catheter revolutionized the concept of guide extension, creating new possibilities in interventional cardiology. Now in its third generation, the GuideLiner V3 Catheter continues to build on a history of innovation and performance — one that has been demonstrated with more than half a million catheters in cath labs around the world.
Teleflex also offers a family of Turnpike Catheters. These contain a robust multi-layer shaft that provides impressive flexibility, torque and tracking over a 0.014” guidewire in complex coronary and peripheral interventions. The unique five-layer composite shaft provides an ideal combination of flexibility and torque response to help navigate through complex anatomy while the outer polymer layer paired with a 60 cm distal hydrophilic coating facilitates smooth catheter delivery. This portfolio consists of the Turnpike Catheter (standard version), the Turnpike Spiral Catheter, the Turnpike Gold Catheter, and the Turnpike LP Catheter. Each catheter configuration contains a specific design element to address various clinical challenges in complex procedures
This year, Teleflex acquired two well-known PTCA balloon catheters. The Chocolate XD PTCA Balloon Catheter is a specialty angioplasty balloon, used in the pre-dilatation and treatment of coronary lesions. The balloon’s proprietary nitinol constraining structure creates “pillows” and “grooves” that are designed to provide controlled dilatation while minimizing vessel wall trauma.
The Glider PTCA Balloon Catheter is a semi-compliant balloon with a skived tip and low entry profile. The tip design, coupled with hydrophilic coating and an innovative, torqueable shaft, allows for precise tip orientation for use in crossing complex lesions and stent struts.
For more information: www.teleflex.com
Chandan Devireddy, M.D., assistant professor of medicine at Emory Healthcare in Atlanta and an investigator in the PARTNER trials, discusses the positive late-breaking PARTNER II and IIA data presented at ACC.16. Among the key measures in these trials was the stroke rate, which is now the same as surgery.
A discussion on the adoption rate of FFR-CT with Dr. Campbell Rogers, chief medical officer of HeartFlow. It is the first vendor to gain FDA approval for noninvasive, virtual fractional flow reserve measurements derived from cardiac computed tomography scans. Read the article "Clinical Applications of FFR-CT."
Gregg Stone, M.D., director of cardiovascular research and education at Columbia University Medical Center / New York-Presbyterian Hospital, explains ABSORB Trial data showing bioresorbable stents had poor outcomes in small coronary vessels. This might be included as a restriction in the instructions for use of the Abbott Absorb stent, which is currently pending FDA final review. Read the related article "Questions Remain on Future of Bioresorbable Stents." Also, read the article "FDA Approves First Totally Bioresorbable Stent."
Dr. Vinod Thourani, professor of surgery, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine and a co-investigator for the PARTNER II Trial, discusses the biggest news item from ACC.16 — the Sapien 3 TAVR device performed better that surgical aortic valve replacement.
Managing inventory in the procedural area is often a challenge that creates substantial waste and inefficiency that impacts your bottom line. Understanding how to overcome the top barriers allows you to spend more time on patient care and less time on tackling your supplies. Learn how you can manage inventory more effectively with Cardinal Health Inventory Management Solutions. For more information visit cardinalhealth.com/cims.
ITN/DAIC Editor Dave Fornell shows his choices for some of the most innovative new imaging technologies on the expo floor at Radiological Society of North America (RSNA) 2015 meeting.
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies presented on the expo floor and in sessions at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting.
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Robert Schwartz, M.D., medical director at the Minnesota Heart Institute, explains new applications for denervation therapies for hypertension, heart failure and other disease.
Guillaume Baillaird, CEO of ControlRad Systems, described how his company's technology can significantly reduce radiation dose to staff and patients during angiography procedures.
Sunil Rao, M.D., associate professor of medicine and a member in the Duke University Clinical Research Institute, a leading proponent of radial access offers insights as to where radial access is at in the United States. Radial access is rapidly growing and was a topic of late-breaking trials presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article "Radial Access Adoption in the United States."
Ziad Ali, M.D., associate director of translational medicine, Columbia University Medical Center / New York-Presbyterian Hospital, explains recent advances in IVUS, OCT and FFR. This was a big topics discussed at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article “10 Reasons Why You Need Supplemental Imaging in the Cath Lab.”
Dr. Stephen Worthley, Ph.D., director of the cardiac cath labs at Royal Adelaide Hospital at the University of Adelaide in Australia, and co-principal investigator of Medtronic's recently launched international drug-filled stent (DFS) clinical trial, explains DFS the new technology. This was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford University Medical Center, explains balloon-based lithoplasty as a new alternative for treating heavily calcified coronary and peripheral vascular disease lesions. The technology was among the new innovations at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Manesh Patel, M.D., associate professor of medicine, and director of interventional cardiology and the cath labs at Duke University, explains the innovations in interventional heart failure technologies, including the Aortix percutaneous heart pump. This was among the innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read more on this device.
Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for both the ABSORB and SYNERGY stent trials, discussed the latest developments in bioresorbable stent technology. Bioresorbable stent technology was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article "FDA Approves First Totally Bioresorbable Stent."
DAIC Editor Dave Fornell shares some of the most innovative new technologies shown on the expo floor and discusses in sessions at the Society of Cardiovascular Computed Tomography (SCCT) 2015 annual meeting.
Interview with James Min, M.D., Professor of Radiology and Medicine and Director of Dalio Institute of Cardiovascular Medicine, Weill Cornell, New York Presbyterian Hospital. Watch the VIDEO “Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation.” A discussion with Simon Dixon, M.D., MBChB, on the use of fractional flow reserve-computed tomography (FFR-CT) to evaluate chest pain patients in the emergency departmenat Beaumont Hospital in Royal Oak, Mich. Read the article "What is New in FFR Technology."
Interview at the American Society of Echocardiography (ASE) annual meeting with Federico Asch, M.D., M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University. He explains how ultrasound might have a roll in the future for breaking up clots and targeted delivery of gene and drug therapies.
Interview with Steve Goldstein, M.D., director, noninvasive lab, Medstar Washington Heart Institute, Washington, D.C., on the uses of echo guidance for interventional procedures in the cath lab.
Role of Interventional Echcardiography in Transcatheter Structural Heart Procedures — Rebecca Hahn, M.D., Columbia University Medical Center, is an expert in the new subspecialty of interventional echo and shares her insights at the Cardiovascular Research Foundation's (CRF) Transcatheter Valve Therapies (TVT) conference in Chicago in June.
Interview with Ted Feldman, M.D., FACC, MSCAI, FESC, cardiac cath lab director, Evanston Hospital, North Shore Health System, and principle investigator, Everest II MitraClip U.S. pivotal trial, at the Transcatheter Valve Therapies 2015 meeting. Watch the VIDEO “Advances and Future Directions for Transcatheter Valves.”
Interview with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation, at the Transcatheter Valve Therapies 2015 meeting. Read the article "Transcatheter Mitral Valve Replacement Devices in Development."
Interview with Charanjit Rihal, M.D., chief of cardiology and professor of medicine, Mayo Clinic, at the Transcatheter Valve Therapies 2015 meeting.
In 2015, the FDA approved the first two drug-coated balloons for the U.S. market to treat peripheral artery disease in the SFA. Doug Drachman, M.D., Mass General Hospital, who served a the site principal investigator for the Lutonix balloon trial, explains his experiences and insights with these devices in an interview at ACC 2015. Read the article “Drug-eluting Balloons Enter the U.S. Market.”
Hear the latest trends and news on interventional cardiology from the American College of Cardiology (ACC) 2015 meeting in an interview with John Reilly, M.D., FACC, vice chairman of cardiology, Ochsner, New Orleans, and chairman of PR, SCAI.
DAIC Editor Dave Fornell shares his picks of the most interesting new devices and advances in cardiovascular technology shown on the expo floor at the 2015 American College of Cardiology (ACC) meeting.
Doug Drachman, M.D., Mass General Hospital Institute of Heart, Vascular and Stroke Care, explains how to prevent and manage access site complications, use of vascular closure devices and how to aid patient ambulation following PCI.
Ziad Ali, M.D., senior scientist at the Cardiovascular Research Foundation (CRF), discusses the current trials and future possibilities of intravascular near-infrared spectroscopy imaging to identify and pre-treat vulnerable plaque.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies discussed in sessions and shown on the expo floor at the Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting.
DAIC Editor, Dave Fornell, interviews Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent Heart Center-Indiana, and a principle investigator in the Absorb III Trial. Read the article "FDA Approves First Totally Bioresorbable Stent."
John Stevens, chairman and CEO of HeartFlow, explains his company's computed tomography (CT)-based fractional flow reserve (FFR) assessment technology, which may eliminate the need for catheter-based FFR measurements.
Peter G. Maxim, Ph.D., assistant professor of radiation oncology at Stanford University, discusses stereotactic radiotherapy for renal sympathetic nerve ablation for the treatment of refractory hypertension, and some of the challenges involved, with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies shown on the expo floor at the American College of Cardiology (ACC) 2014 meeting.
Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of Cardiology (ACC) 2014 meeting. Doug Drachman, M.D., Mass General Hospital, explains where the technology is today and what we will likely see in the future. Read the article "FDA Approves First Totally Bioresorbable Stent."
The biggest late-breaking news to come out of the American College of Cardiology (ACC) 2014 meeting was from the CoreValve High-Risk pivotal trial, which showed a transcatheter valve offers a 26 percent survival benefit over surgical valve replacement. Co-Principal Investigator David Adams, M.D., explained the impact of the trial.
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial. Michael Jaff , D.O., worked as part of the core lab for the trial and explains the trial outcomes and the future of renal denervation technology.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies discussed in sessions and shown on the expo floor at the Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting.
Scott Lim, M.D., director of the Heart Valve Center at the University of Virginia Medical Center, investigator in the EVEREST and COAPT trials, discusses the MitraClip transcatheter mitral valve repair system at TCT 2013. The device recieved FDA clearance a couple days before TCT.